AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway

Xu,Hailiang; Feng,Yunyun; Jia,Zhankui; Yang,Jinjian; Lu,Xueren; Li,Jun; Xia,Mingliang; Wu,Chunru; Zhang,Yonggang; Chen,Jianhua

doi:10.3892/ol.2017.6214

AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway

Authors:
- Hailiang Xu
- Yunyun Feng
- Zhankui Jia
- Jinjian Yang
- Xueren Lu
- Jun Li
- Mingliang Xia
- Chunru Wu
- Yonggang Zhang
- Jianhua Chen
View Affiliations

Affiliations: Department of Urinary Surgery, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China, Department of Pediatrics, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China, Department of Urinary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Gynecology, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China, Department of Emergency, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China, Department of General Surgery, The Zhumadian City Center Hospital, Zhumadian, Henan 463000, P.R. China
Published online on: May 19, 2017 https://doi.org/10.3892/ol.2017.6214
Pages: 981-986

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Axis inhibition protein 1 (AXIN1) is characterized as a tumor suppressor in numerous types of cancer. However, the functional role of AXIN1 in the testicular germ cell tumors (TGCTs) remains unclear. The human embryonal carcinoma-derived cell line NTera2 was transfected with a recombinant AXIN1 expression vector (pcDNA3.1‑AXIN1) and/or a small interfering RNA (siRNA) directed against AXIN1 (siAXIN). Following transfection, the mRNA and protein levels of AXIN1 were determined via reverse transcription‑quantitative polymerase chain reaction analysis and western blotting, respectively. In addition, cell viability, apoptosis and the expression of apoptosis‑associated proteins [apoptosis regulator Bax (Bax) and B‑cell lymphoma (Bcl)‑2] and phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway proteins [phosphorylated (p)‑mTOR, mTOR, p‑AKT, AKT, P‑70S ribosomal protein S6 (S6) and S6] were assessed. AXIN1 mRNA and protein levels were increased following transfection with pcDNA3.1‑AXIN1 and decreased following transfection with siAXIN1 compared with their respective control groups. After overexpression of AXIN1, NTera2 cell viability and expression of Bcl‑2, p‑mTOR p‑AKT and p‑S6 protein was decreased, while apoptosis and Bax protein levels were increased, compared with the control group. However, there was no significant difference in AXIN1 mRNA expression, apoptosis or Bax/Bcl‑2 protein expression when NTera2 cells were simultaneously transfected with pcDNA3.1‑AXIN1+siAXIN1. In conclusion, the results of the present study indicate that overexpression of AXIN1 protects against TGCTs via inhibiting the PI3K/AKT/mTOR signaling pathway, suggesting that AXIN1 may be a potential target for gene therapy in TGCTs.

View Figures

View References

1	Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB and McGlynn KA: International trends in the incidence of testicular cancer, 1973–2002. Cancer Epidemiol Biomarkers Prev. 19:1151–1159. 2010. View Article : Google Scholar : PubMed/NCBI
2	Vasdev N, Moon A and Thorpe AC: Classification, epidemiology and therapies for testicular germ cell tumours. Int J Dev Biol. 57:133–139. 2013. View Article : Google Scholar : PubMed/NCBI
3	Purdue MP, Devesa SS, Sigurdson AJ and McGlynn KA: International patterns and trends in testis cancer incidence. Int J Cancer. 115:822–827. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ries LAG, Young JL Jr, Keel GE, Eisner MP, Lin YD and Horner M-JD: SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001. Patient and Tumor CharacteristicsNational Cancer Institute, SEER Program, NIH Pub. No. 07-6215. Bethesda, MD: 2007
5	Hayes-Lattin B and Nichols CR: Testicular cancer: A prototypic tumor of young adults. Semin Oncol. 36:432–438. 2009. View Article : Google Scholar : PubMed/NCBI
6	Raghavan D: Testicular cancer: Maintaining the high cure rate. Oncology (Williston Park). 17:218–229, 234-235. 2003.PubMed/NCBI
7	Li J, Quan H, Liu Q, Si Z, He Z and Qi H: Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B virus-related hepatocellular carcinoma and overexpression of AXIN1 induces apoptosis in hepatocellular cancer cells. Oncol Res. 20:281–288. 2013. View Article : Google Scholar : PubMed/NCBI
8	Salahshor S and Woodgett JR: The links between axin and carcinogenesis. J Clin Pathol. 58:225–236. 2005. View Article : Google Scholar : PubMed/NCBI
9	Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY and Park CK: Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 25:70–76. 2005. View Article : Google Scholar : PubMed/NCBI
10	Mazzoni SM and Fearon ER: AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett. 355:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
11	Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al: AXIN1 mutations in hepatocellular carcinomas and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 24:245–250. 2000. View Article : Google Scholar : PubMed/NCBI
12	Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S and Kikuchi A: Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem. 273:10823–10826. 1998. View Article : Google Scholar : PubMed/NCBI
13	Deng F, Li S, Xu W, Zou Z, Ke Z and Zeng F: AXIN1-related CSRNP1 mRNA expression and its transcriptional regulation in TGF-beta1-induced tumor cells. Nan Fang Yi Ke Da Xue Xue Bao. 33:1122–1126. 2013.(In Chinese). PubMed/NCBI
14	Zhang Y, Neo SY, Wang X, Han J and Lin SC: Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J Biol Chem. 274:35247–35254. 1999. View Article : Google Scholar : PubMed/NCBI
15	Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W, Zhou HM, Cheung PY, Wu Z, Ye Z, et al: Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 23:4583–4594. 2004. View Article : Google Scholar : PubMed/NCBI
16	Fritsch MK, Schneider DT, Schuster AE, Murdoch FE and Perlman EJ: Activation of Wnt/beta-catenin signaling in distinct histologic subtypes of human germ cell tumors. Pediatr Dev Pathol. 9:115–131. 2006. View Article : Google Scholar : PubMed/NCBI
17	Dahmen RP, Koch A, Denkhaus D, Tonn JC, Sörensen N, Berthold F, Behrens J, Birchmeier W, Wiestler OD and Pietsch T: Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 61:7039–7043. 2001.PubMed/NCBI
18	Ngalame NN, Tokar EJ, Person RJ and Waalkes MP: Silencing KRAS overexpression in arsenic-transformed prostate epithelial and stem cells partially mitigates malignant phenotype. Toxicol Sci. 142:489–496. 2014. View Article : Google Scholar : PubMed/NCBI
19	Figeac N and Zammit PS: Coordinated action of Axin1 and Axin2 suppresses β-catenin to regulate muscle stem cell function. Cell Signal. 27:1652–1665. 2015. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL III, Lee JJ, Tilghman SM, Gumbiner BM and Costantini F: The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 90:181–192. 1997. View Article : Google Scholar : PubMed/NCBI
22	de la Roche M, Ibrahim AE, Mieszczanek J and Bienz M: LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res. 74:1495–1505. 2014. View Article : Google Scholar : PubMed/NCBI
23	Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
24	L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors. Int J Oncol. 29:5–24. 2006.PubMed/NCBI
25	Rada P, Rojo AI, Offergeld A, Feng GJ, Velasco-Martín JP, González-Sancho JM, Valverde ÁM, Dale T, Regadera J and Cuadrado A: WNT-3A regulates an Axin1/NRF2 complex that regulates antioxidant metabolism in hepatocytes. Antioxid Redox Signal. 22:555–571. 2015. View Article : Google Scholar : PubMed/NCBI
26	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
27	Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014. View Article : Google Scholar : PubMed/NCBI
28	Polivka J Jr and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
29	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
30	Burris HA III: Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
31	Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S, Galvani E, et al: Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 323:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
32	Stern DF: ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 13:215–223. 2008. View Article : Google Scholar : PubMed/NCBI
33	Zhao L and Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene. 27:5486–5496. 2008. View Article : Google Scholar : PubMed/NCBI
34	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
35	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
36	Grewe M, Gansauge F, Schmid RM, Adler G and Seufferlein T: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 59:3581–3587. 1999.PubMed/NCBI
37	Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, Robin NC, Dawson DW, Moon RT and Chien AJ: Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal. 5:ra32012. View Article : Google Scholar : PubMed/NCBI
38	Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, Tokarz S, Morgan C and Sears RC: The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 28:500–512. 2009. View Article : Google Scholar : PubMed/NCBI